Wednesday, March 05, 2025 | 03:14 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Jubilant Life falls 6% as USFDA recommends action on failing inspection

The stock dipped 6% to Rs 742 on the BSE after the US health regulator recommended a regulatory or administrative action after the inspection of the drug firm's Roorkee manufacturing facility.

Drugs, Pill, Medicine, Tablet
Premium

SI Reporter Mumbai
Shares of Jubilant Life Sciences have dipped 6% to Rs 742 per share on the BSE in early morning trade after the US health regulator recommended a regulatory or administrative action after the inspection of the drug firm's Roorkee manufacturing facility.

“In response to the US Food & Drug Administration (USFDA) inspection conducted at its Roorkee facility of solid dosage formulations during August 2018, the agency has informed to classify the inspection as “Official Action Indicated” (OAI) and that approvals of pending applications or supplements from this site maybe withheld,” Jubilant Life Sciences said in a regulatory filing on Saturday, December

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in